Latest stories on MRK
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
24/7 Wall St.42 · neutralearnings
Merck (MRK) reports Q3: everything you need to know ahead of earnings
Barchart50 · neutralearnings
AstraZeneca is said to be considering cancer vaccine development
Seeking Alpha63 · neutralproduct/pr
Cantor Fitzgerald reiterates Neutral on Merck stock at $145
Investing.com Analyst Ratings50 · neutralanalyst
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
MarketBeat42 · neutralproduct/pr
Merck & Co., Inc. (MRK) Shareholder/Analyst Presentation - Slideshow
Seeking Alpha50 · neutralgeneral
Merck & Co Inc Investor Event at ESMO Transcript
GuruFocus52 · neutralproduct/pr
Moderna CEO Says Its Cancer Vaccine Isn’t a Disappointment, It’s a Blockbuster
Barron's58 · neutralproduct/pr
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Seeking Alpha50 · neutralgeneral
Merck's sac-TMT significantly cuts death risk in endometrial cancer
Seeking Alpha74 · bullishproduct/pr
Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027
Stocktwits News74 · bullishproduct/pr
Merck says Keytruda reduced risk of disease progression in endometrial cancer
The Fly64 · neutralproduct/pr
Merck reports sac-TMT reduced risk of death by 32% in TroFuse-005 trial
The Fly74 · bullishproduct/pr
Merck Drug Boosts Survival From Hard-to-Treat Uterine Cancer
Bloomberg74 · bullishproduct/pr
Moderna and Merck's personalized mRNA cancer vaccine cut melanoma recurrence risk by 42%
Quartz74 · bullishproduct/pr
Merck price target raised to $180 from $150 at Barclays
The Fly64 · neutralanalyst
Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
Stocktwits News55 · neutralearnings
Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29
24/7 Wall St.57 · neutralearnings
AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?
24/7 Wall St.52 · neutralgeneral
Merck/Moderna's Melanoma Combination Therapy Delivers Promising Phase 3 Trial Results
Seeking Alpha74 · bullishproduct/pr
Will These Nuances Undo Merck And Moderna's Cancer Vaccine?
Investors.com44 · neutralgeneral
Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’
Stocktwits News58 · neutralproduct/pr
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
CNBC58 · neutralproduct/pr